Related company info
Ingrid Lee, Taipei; Steve Shen, DIGITIMES
Thursday 11 October 2012
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$30 on the TSE on Thursday, May 24, 2018.
    The company has reported consolidated revenues of NT$153 million for April 2018, representing a 3.9% increase on month and 12.2% increase on year.
    For the first quarter of 2018, the company totaled NT$470 million in consolidated revenues, down 0.3% sequentially and up 10.7% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$997.27 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    25-May 48   30.05 30.10 29.95 29.95-0.05-0.17%  
    24-May 310 199 9,306,700 30.20 30.25 29.95 30.00+0.00+0.00% 30.00 30.05
    23-May 360 215 10,807,650 30.05 30.20 29.95 30.00-0.05-0.17% 30.00 30.10
    22-May 302 193 9,065,800 30.30 30.30 29.95 30.05-0.15-0.50% 29.95 30.05
    21-May 343 220 10,336,350 30.30 30.30 30.00 30.20+0.20+0.67% 30.15 30.20
    18-May 277 188 8,310,000 30.20 30.20 29.90 30.00+0.10+0.33% 29.90 30.00
    17-May 367 195 11,014,450 30.15 30.15 29.90 29.90-0.15-0.50% 29.90 29.95
    16-May 416 221 12,529,638 30.05 30.30 29.90 30.05+0.00+0.00% 29.95 30.05
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Apr 2017 - Apr 2018 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Apr-18

    153

    3.9%

    12.2%

    629

    12.1%

    Mar-18

    147

    (6.5%)

    (16%)

    476

    12%

    Feb-18

    158

    (8%)

    59.6%

    329

    31.7%

    Jan-18

    171

    9.5%

    13.5%

    171

    13.5%

    Dec-17

    156

    9.7%

    62.2%

    1,795

    1.8%

    Nov-17

    143

    (17.7%)

    3.2%

    1,639

    (1.7%)

    Oct-17

    173

    12.6%

    28.8%

    1,496

    (2.1%)

    Sep-17

    154

    5.4%

    17.5%

    1,323

    (5.1%)

    Aug-17

    146

    (18.4%)

    19.3%

    1,169

    (7.4%)

    Jul-17

    179

    16.7%

    19.1%

    1,024

    (10.3%)

    Jun-17

    153

    17.6%

    (4.5%)

    845

    (14.8%)

    May-17

    130

    (4.6%)

    (21.7%)

    692

    (16.7%)

    Apr-17

    136

    (22.2%)

    (25.2%)

    561

    (15.5%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2018

    Apex: Consolidated revenues, 1Q17 - 1Q18 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    1Q-18

    470

    (0.3%)

    10.7%

    470

    10.7%

    4Q-17

    472

    (1.3%)

    27.9%

    1,795

    1.8%

    3Q-17

    478

    14%

    18.7%

    1,323

    (5.1%)

    2Q-17

    420

    (1.2%)

    (17.5%)

    845

    (14.8%)

    1Q-17

    425

    15.2%

    (11.8%)

    425

    (11.8%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2018

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 1Q17 - 1Q18 (NT$k)

    Item

    1Q-2018

    4Q-2017

    3Q-2017

    2Q-2017

    1Q-2017

    Current assets

    1,662,287

    1,598,533

    1,576,999

    1,632,388

    1,647,085

    Intangible assets

    282,502

    294,089

    304,638

    314,386

    25,010

    Non-current assets

    1,053,702

    1,101,248

    1,124,705

    1,143,758

    880,663

    Assets

    2,715,989

    2,699,781

    2,701,704

    2,776,146

    2,527,748

    Current liabilities

    1,005,943

    1,018,272

    1,062,660

    818,230

    482,436

    Non-current liabilities

    15,511

    16,642

    17,492

    355,661

    354,649

    Liabilities

    1,021,454

    1,034,914

    1,080,152

    1,173,891

    837,085

    Stockholders' equity

    1,694,535

    1,664,867

    1,621,552

    1,602,255

    1,690,663

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2018

    Apex: Consolidated income statement, 1Q17 - 1Q18 (NT$k)

    Item

    1Q-2018

    4Q-2017

    3Q-2017

    2Q-2017

    1Q-2017

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Gross sales

     

     

     

     

    478,449

     

    419,801

     

    424,990

     

    Operating revenue

    470,455

    98.3%

    472,060

    98.7%

    478,449

    100%

    419,801

    100%

    424,990

    100%

    Gross profit (loss) from operations

    124,684

    26.1%

    163,763

    34.2%

    102,951

    21.5%

    89,252

    21.3%

    75,548

    17.8%

    Operating expenses

    79,984

    16.7%

    84,407

    17.6%

    77,552

    16.2%

    47,662

    11.4%

    60,894

    14.3%

    Operating income (loss)

    44,700

    9.3%

    79,356

    16.6%

    25,399

    5.3%

    41,590

    9.9%

    14,654

    3.4%

    Non-operating expenses and losses

    -17,592

    -3.7%

    -18,114

    -3.8%

    3,629

    0.8%

    19,106

    4.6%

    -53,646

    -12.6%

    Income from continuing operations before income tax

    27,108

    5.7%

    61,242

    12.8%

    29,028

    6.1%

    60,696

    14.5%

    -38,992

    -9.2%

    Net income (loss)

     

     

    43,611

    9.1%

    20,501

    4.3%

    57,277

    13.6%

    -38,992

    -9.2%

    Diluted earnings per share (NT$)

    0.2

     

    0.4

     

    0.2

     

    0

     

    -0.4

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, May 2018

  • Apex Biotechnology full profile
Realtime news

Taiwan large-size LCD panels – 1Q 2018

China smartphone AP shipments – 1Q 2018

Taiwan small- to mid-size LCD panels – 1Q 2018

Global AP market, 2017-2021

Taiwan server shipment forecast and industry analysis, 2018

China AMOLED panel capacity expansion forecast, 2016-2020

© DIGITIMES Inc. All rights reserved.
Please do not republish, publicly broadcast or publicly transmit content from this website without written permission from DIGITIMES Inc. Please contact us if you have any questions.